379 related articles for article (PubMed ID: 26503643)
41. A simple score derived from bone marrow immunophenotyping is important for prognostic evaluation in myelodysplastic syndromes.
Vido-Marques JR; Reis-Alves SC; Saad STO; Metze K; Lorand-Metze I
Sci Rep; 2020 Nov; 10(1):20281. PubMed ID: 33219285
[TBL] [Abstract][Full Text] [Related]
42. Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations.
Alhan C; Westers TM; Cremers EM; Cali C; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2016 Jul; 90(4):358-67. PubMed ID: 26517178
[TBL] [Abstract][Full Text] [Related]
43. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
[TBL] [Abstract][Full Text] [Related]
44. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
[TBL] [Abstract][Full Text] [Related]
45. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
[TBL] [Abstract][Full Text] [Related]
46. [Role of flow cytometric immunophenotyping in diagnosis of myelodysplastic syndromes--review].
Zhang Y; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1477-81. PubMed ID: 19099668
[TBL] [Abstract][Full Text] [Related]
47. PAS positivity of erythroid precursor cells is associated with a poor prognosis in newly diagnosed myelodysplastic syndrome patients.
Masuda K; Shiga S; Kawabata H; Takaori-Kondo A; Ichiyama S; Kamikubo Y
Int J Hematol; 2018 Jul; 108(1):30-38. PubMed ID: 29600427
[TBL] [Abstract][Full Text] [Related]
48. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
Zeidan AM; Sekeres MA; Wang XF; Al Ali N; Garcia-Manero G; Steensma DP; Roboz G; Barnard J; Padron E; DeZern A; Maciejewski JP; List AF; Komrokji RS;
Am J Hematol; 2015 Nov; 90(11):1036-40. PubMed ID: 26284571
[TBL] [Abstract][Full Text] [Related]
49. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.
Sandes AF; Kerbauy DM; Matarraz S; Chauffaille Mde L; López A; Orfao A; Yamamoto M
Cytometry B Clin Cytom; 2013 May; 84(3):157-66. PubMed ID: 23475532
[TBL] [Abstract][Full Text] [Related]
50. [Value of multiparameter flow cytometry in the diagnosis and prognostic evaluation of childhood myelodysplastic syndrome].
Liu C; An WB; Zhang JL; Zhang RR; Sun CC; Chang LX; Liu TF; Zou Y; Wang HJ; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Oct; 20(10):819-824. PubMed ID: 30369356
[TBL] [Abstract][Full Text] [Related]
51. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes.
Cherian S; Moore J; Bantly A; Vergilio JA; Klein P; Luger S; Bagg A
Cytometry B Clin Cytom; 2005 Mar; 64(1):9-17. PubMed ID: 15668954
[TBL] [Abstract][Full Text] [Related]
52. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.
Xu F; Li X; Wu L; He Q; Zhang Z; Chang C
Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463
[TBL] [Abstract][Full Text] [Related]
53. [Application of Two-parameter Scoring System Based on CD105 and CD117 in MDS Diagnosis].
Zheng C; Wang YZ; Yuan XY; Chang Y; Shi HX; Lai YY; Huang XJ; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):141-148. PubMed ID: 30738461
[TBL] [Abstract][Full Text] [Related]
54. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients.
Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores-Montero J; Rasillo A; Sayagues JM; Sánchez ML; Bárcena P; Hernandez-Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Laranjeira P; Paiva A; Orfao A
Cytometry B Clin Cytom; 2010 May; 78(3):154-68. PubMed ID: 20198685
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes.
Verigou E; Lampropoulou P; Smyrni N; Kolliopoulou G; Sakellaropoulos G; Starakis I; Zikos P; Solomou E; Symeonidis A; Karakantza M
Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):148-61. PubMed ID: 26126819
[TBL] [Abstract][Full Text] [Related]
56. A multiparametric flow cytometry immunophenotypic scoring system for the diagnosis and prognosis of myelodysplastic syndromes.
Huang J; Lai P; Zhou M; Weng J; Lu Z; Du X
Clin Lab; 2012; 58(11-12):1241-51. PubMed ID: 23289195
[TBL] [Abstract][Full Text] [Related]
57. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.
Hou HA; Tsai CH; Lin CC; Chou WC; Kuo YY; Liu CY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Yao M; Tang JL; Tien HF
Blood Cancer J; 2018 Apr; 8(4):39. PubMed ID: 29618722
[TBL] [Abstract][Full Text] [Related]
58. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.
Della Porta MG; Picone C; Pascutto C; Malcovati L; Tamura H; Handa H; Czader M; Freeman S; Vyas P; Porwit A; Saft L; Westers TM; Alhan C; Cali C; van de Loosdrecht AA; Ogata K
Haematologica; 2012 Aug; 97(8):1209-17. PubMed ID: 22315489
[TBL] [Abstract][Full Text] [Related]
59. The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience.
Majcherek M; Kiernicka-Parulska J; Mierzwa A; Barańska M; Matuszak M; Lewandowski K; Komarnicki M; Czyż A
Scand J Immunol; 2021 Aug; 94(2):e13028. PubMed ID: 33577137
[TBL] [Abstract][Full Text] [Related]
60. A combination of CD15/CD10, CD64/CD33, CD16/CD13 or CD11b flow cytometric granulocyte panels is sensitive and specific for diagnosis of myelodysplastic syndrome.
Chung JW; Park CJ; Cha CH; Cho YU; Jang S; Chi HS; Seo EJ; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ
Ann Clin Lab Sci; 2012; 42(3):271-80. PubMed ID: 22964615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
